Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To estimate response rates (CR + CCR + PR) according to CD25 status (CD25 positive and negative) after 4 cycles of ONTAK.
Francine Foss, M.D.
United States: Food and Drug Administration
|University Hospitals of Cleveland||Cleveland, Ohio 44106|
|City of Hope National Medical Center||Los Angeles, California 91010|
|University of Pittsburgh||Pittsburgh, Pennsylvania 15261|
|Vanderbilt University||Nashville, Tennessee 37232-6305|
|Ohio State University||Columbus, Ohio 43210|
|New England Medical Center||Boston, Massachusetts|
|Yale University School Of Medicine||New Haven, Connecticut 06520|
|The University of Texas MD Anderson Cancer Center||Houston, Texas 77030-4009|
|The University of Iowa||Iowa City, Iowa 52242|